FDA Finds Gaps at Another Indian Drugmaker
NEW DELHI: The US Food and Drug Administration (FDA) has found nine deviations in Indian drug maker Cipla's manufacturing process during a recent inspection of the company's Bangalore plant. The Mumbai-based company, however, said the deviations are minor ones relating to manufacturing practices.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.